LEADER 04437nam 22006735 450 001 9910300188803321 005 20200629225648.0 010 $a3-319-10527-2 024 7 $a10.1007/978-3-319-10527-7 035 $a(CKB)3710000000277652 035 $a(EBL)1965464 035 $a(OCoLC)908083467 035 $a(SSID)ssj0001386404 035 $a(PQKBManifestationID)11746807 035 $a(PQKBTitleCode)TC0001386404 035 $a(PQKBWorkID)11374344 035 $a(PQKB)10485319 035 $a(DE-He213)978-3-319-10527-7 035 $a(MiAaPQ)EBC1965464 035 $a(PPN)183088840 035 $a(EXLCZ)993710000000277652 100 $a20141110d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aClinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials$b[electronic resource] /$fby Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Adis,$d2015. 215 $a1 online resource (149 p.) 300 $aDescription based upon print version of record. 311 $a3-319-10526-4 320 $aIncludes bibliographical references at the end of each chapters. 327 $aIntroduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions. 330 $aThis comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested.  In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs. . 606 $aTropical medicine 606 $aHealth promotion 606 $aPharmacy 606 $aTropical Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H61006 606 $aHealth Promotion and Disease Prevention$3https://scigraph.springernature.com/ontologies/product-market-codes/H27010 606 $aDrug Safety and Pharmacovigilance$3https://scigraph.springernature.com/ontologies/product-market-codes/H69010 615 0$aTropical medicine. 615 0$aHealth promotion. 615 0$aPharmacy. 615 14$aTropical Medicine. 615 24$aHealth Promotion and Disease Prevention. 615 24$aDrug Safety and Pharmacovigilance. 676 $a353998 676 $a610 676 $a613 676 $a614.44 700 $aKiang$b Tony K.L$4aut$4http://id.loc.gov/vocabulary/relators/aut$0789386 702 $aWilby$b Kyle John$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aEnsom$b Mary H.H$4aut$4http://id.loc.gov/vocabulary/relators/aut 906 $aBOOK 912 $a9910300188803321 996 $aClinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials$92519593 997 $aUNINA